Blood cancers can be tough to beat. But there is hope. One method that has shown promise is allogeneic peripheral-blood stem-cell transplantation. This is a fancy way of saying using stem cells from a matched related donor. This process is often used after a patient has gone through myeloablative conditioning. That is a strong treatment to wipe out the diseased bo...

Cancer treatment has seen a major boost with the introduction of allogeneic cell-based therapies. These treatments, especially CAR-T cell therapy, are a big deal because they can be made in large quantities and are consistent. However, there is a significant hurdle: graft-versus-host disease (GvHD). This occurs when the transplanted cells attack the patient's body. R...

A recent study explored the use of post-transplant high-dose cyclophosphamide (PTCy) in haematopoietic cell transplantation (HCT) from mismatched unrelated donors (MMUD) in patients with acute myeloid malignancies. The research focused on whether PTCy, along with a calcineurine inhibitor and mycophenolate mofetil, could improve outcomes and reduce the incidence ...